Psoriasis

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

Versus placebo, topical melatonin and rosuvastatin reduced psoriatic plaque severity with a favorable safety profile.

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.

Learn more about the in-depth topics covered in the March 2024 enhancing psoriasis management supplement of Dermatology Times.

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

We take a look at various studies exploring the relationship between psoriasis and COVID-19 vaccination, the link between COVID-19 and psoriasis severity, and more.

The expanded approval of Spevigo follows the Chinese National Medical Products Administration’s approval for the injection for the reduction of occurrence of GPP.

A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Patients with psoriatic disease face an increased risk of cardiovascular disease. Clinicians should consider this when determining management and treatment modalities for patients with psoriasis.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.

Psoriasis is linked to a heightened risk of cardiovascular disease, necessitating proactive screening, collaborative care, and consideration of potential impacts of psoriasis treatments on cardiovascular health.

As a pharmacy benefit manager, Livinti will help reduce biologic drug costs for self-funded employees.

A recent study identified an association between psoriasis severity and IBD, Crohn disease, and ulcerative colitis.

Biologics to treat psoriasis can cost between $1664 and $79,277 a year in the United States, one study found, and these prices are not commensurate with clinical benefits.

Get a sneak peek ahead of AAD about the LITE study’s patient-centered design, routine care integration, and diverse participant inclusion, offering a cost-effective option in psoriasis treatment.

Findings reveal an increased risk of psoriatic arthritis among female patients with severe skin psoriasis who have nail involvement and require oral systemic therapy for their condition.

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Joel Gelfand, MD, explained how body surface area on patients with psoriasis plays a pivotal role in cardiovascular outcomes.

Alice Gottlieb, MD, PhD, put a spotlight on recent studies and the current psoriasis treatment armamentarium for dermatology clinicians to consider.

The IFPA Forum Roadmap for Asia outlines key advocacy demands and practical strategies to improve psoriatic care throughout the continent.

Artax announced that safety and efficacy data is expected in the second half of the year.

A new study suggests patients with psoriasis may experience exacerbated disease burden waiting to initiate systemic treatment.

Data from the FRONTIER 1 clinical trial were recently published in the New England Journal of Medicine.

The VISIBLE clinical program will create a longitudinal collection of more than 20,000 clinical images across all skin tones.

New evidence identifies factors that may predict which patients with psoriasis will develop psoriatic arthritis.